ArticleGene therapy2022

CRISPR editing as a therapeutic strategy for Duchenne muscular dystrophy-anti-Cas9 immune response casts its shadow over safety and efficacy.

James J DowlingPubMed ↗Publisher ↗

No numbers read from the abstract.